Happy news filtered down Thursday from the fight against arthritis, from a company which evidently believes in thinking outside the box.
San Diego-based Regen BioPharma Inc. (OTC:RGBP) announced positive data demonstrating that its novel cannabidiol-based therapeutic approach successfully reduces rheumatoid arthritis in an animal model.
The data disclosed today, which is the subject of a United States patent application, show that the Company's drug candidate induces activation of a type of immune system cell termed "T Regulatory Cells".
The immunology community believes that T regulatory cells serve a fundamental role in protecting the body from uncontrolled inflammation or autoimmunity.
Autoimmune diseases are conditions in which the immune system starts attacking components of the body. Major autoimmune conditions include rheumatoid arthritis, multiple sclerosis, type 1 diabetes, and lupus.
Said CEO David Koos, "These current findings add another therapeutic candidate to our existing portfolio which centers of modulation of inflammatory pathways such as NR2F6.
"What this means to our small molecule drug development programs is CBD appears when used with other compounds to amplify the desired outcome."
Shares in RGBP rocketed 66.7% to reach 15-100ths of a cent early Thursday afternoon, on volume of 113 million shares.
Related Stories
